10 Quality Value Stocks Likely to Make a Comeback According to Analysts

7. Insulet Corporation (NASDAQ:PODD)

Price Target Upside: 58.53%

Insulet Corporation (NASDAQ:PODD) is among the best value stocks.

TheFly reported on March 13 that Truist observed that PODD shares declined after the company disclosed a Voluntary Device Correction for certain Omnipod 5 lots. While competition in the patch pump market could use the announcement as a minor negative, the reported 18 serious adverse events, including hospitalizations and DKA, involved no fatalities and are expected to have a limited financial effect. Insulet confirmed guidance remains unchanged, and related remediation costs will be excluded from non-GAAP results. Truist considers the stock’s decline to be more severe than justified by potential financial or market-share consequences and maintains a Buy rating with a price target on the shares.

Just days before the device correction, on March 11, Insulet Corporation (NASDAQ:PODD) reported encouraging clinical findings from its EVOLUTION 2C study at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The multicenter feasibility trial evaluated the company’s fully closed-loop automated insulin delivery system for type 2 diabetes in 24 adults, aged 16–70, from a diverse cohort.

Using the final algorithm without boluses, participants’ time in range rose to 68%, a 24% gain over standard injection therapy, while time below range remained minimal at 0.14%. No severe hypoglycemia or DKA occurred, demonstrating improved glucose control without safety compromises across varied participant profiles.

Insulet Corporation (NASDAQ:PODD) is a medical device company that designs, manufactures, and sells the Omnipod insulin management system, a tubeless, wearable insulin pump that helps people with diabetes simplify and personalize their insulin delivery.